Bioanalytical Approaches to Quantify 'Total' and 'Free' Therapeutic Antibodies and Their Targets: Technical Challenges and PK/PD Applications Over the Course of Drug Development
| Autor: | Ago B. Ahene, Jihong Yang, Hossein Salimi-Moosavi, Meina T. Tang, Jian-Feng Lu, John Kamerud, Heather Myler, Lindsay King, Jean W. Lee, Marian Kelley, Cindy Rogers |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Bioanalysis
Chemistry medicine.drug_class Ligand binding assay Receptors Drug Pharmaceutical Science White Paper Antibodies Monoclonal Computational biology Pharmacology Monoclonal antibody Ligands Pharmacokinetics Drug development In vivo Pharmacodynamics Drug Design medicine Animals Humans PK/PD models Algorithms |
| Popis: | The predominant driver of bioanalysis in supporting drug development is the intended use of the data. Ligand-binding assays (LBA) are widely used for the analysis of protein biotherapeutics and target ligands (L) to support pharmacokinetics/pharmacodynamics (PK/PD) and safety assessments. For monoclonal antibody drugs (mAb), in particular, which non-covalently bind to L, multiple forms of mAb and L can exist in vivo, including free mAb, free L, and mono- and/or bivalent complexes of mAb and L. Given the complexity of the dynamic binding equilibrium occurring in the body after dosing and multiple sources of perturbation of the equilibrium during bioanalysis, it is clear that ex vivo quantification of the forms of interest (free, bound, or total mAb and L) may differ from the actual ones in vivo. LBA reagents and assay formats can be designed in principle to measure the total or free forms of mAb and L. However, confirmation of the forms being measured under the specified conditions can be technically challenging. The assay forms and issues must be clearly communicated and understood appropriately by all stakeholders as the program proceeds through the development process. This paper focuses on monoclonal antibody biotherapeutics and their circulatory L that are either secreted as soluble forms or shed from membrane receptors. It presents an investigation into the theoretical and practical considerations for total/free analyte assessment to increase awareness in the scientific community and offer bioanalytical approaches to provide appropriate PK/PD information required at specific phases of drug development. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|